Skip to main content

JHOP - December 2026 Vol 16, No 6

Original Research
Original Research
Online First
Original Research, Adverse Events, PARP Inhibitors, Dose Escalation/Reduction
Incidence of PARP Inhibitor Adverse Events Between Germline Versus Somatic Homologous Recombination Mutations
Lauren S. Yeager, PharmD, BCOP; C. Scott Ellis, PharmD, BCOP; Danielle Otto, PharmD, BCOP; Justine Pickarski, MS, LGC; Taylor A. Rives, MD; Aric Schadler, PhD, et al.
Read More
Online First
Original Research, Chemotherapy, Oncology Pharmacy Programs/Protocols, Supportive Care, Breast Cancer
Impact of Pharmacist-Driven Oral Chemotherapy Treatment Plan Implementation on Monitoring and Supportive Care Interventions During CDK4/6 Inhibitor Therapy for Patients With Breast Cancer
Morgan Felitte, PharmD; Hannah Kisla, PharmD, BCOP; Elizabeth Brady, PharmD, CSP; Darlene Tat, PharmD, MPH; Jessica Mills, PharmD; Jennifer McDonald, PharmD, BCPS
Read More
Online First
Original Research, Methotrexate, Case Reports
Glucarpi-CAP: A Retrospective Case Series of 1000-Unit Glucarpidase Dosing for Methotrexate Rescue
Sydney Ertz, PharmD; Joseph Bubalo, PharmD, BCOP, FHOPA
Read More
Online First
Original Research, Bispecific Antibodies, Multiple Myeloma
Expanding Bispecific T-Cell Engager Therapy for Multiple Myeloma to Community Settings: A Single-Institution Experience
Rahim Jiwani, MD; Samantha Maples, PharmD; Srinishant Rajarajan, MD; Kalaivani Babu, MD; Santhosh Sadashiv, MD; Prerna Mewawalla, MD
Read More
Online First
Original Research, Immunotherapy, Chemotherapy, Breast Cancer
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges, PharmD; Katelyn Patterson, PharmD; Vera Ljucovic, PharmD
Read More